These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 14576498)

  • 1. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
    Schmidt CM; Wang Y; Wiesenauer C
    J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
    Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
    Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
    Cusimano A; Foderà D; D'Alessandro N; Lampiasi N; Azzolina A; Montalto G; Cervello M
    Cancer Biol Ther; 2007 Sep; 6(9):1461-8. PubMed ID: 18424914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.
    Rice PL; Washington M; Schleman S; Beard KS; Driggers LJ; Ahnen DJ
    Cancer Res; 2003 Feb; 63(3):616-20. PubMed ID: 12566304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
    Yip-Schneider MT; Wiesenauer CA; Schmidt CM
    J Gastrointest Surg; 2003; 7(3):354-63. PubMed ID: 12654560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
    Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
    Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.
    Ding XZ; Adrian TE
    Biochem Biophys Res Commun; 2001 Mar; 282(2):447-53. PubMed ID: 11401480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
    Elder DJ; Halton DE; Playle LC; Paraskeva C
    Int J Cancer; 2002 May; 99(3):323-7. PubMed ID: 11992399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
    Hu Y; Bally M; Dragowska WH; Mayer L
    Mol Cancer Ther; 2003 Jul; 2(7):641-9. PubMed ID: 12883037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
    Yip-Schneider MT; Sweeney CJ; Jung SH; Crowell PL; Marshall MS
    J Pharmacol Exp Ther; 2001 Sep; 298(3):976-85. PubMed ID: 11504793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
    Guha S; Lunn JA; Santiskulvong C; Rozengurt E
    Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.